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Abstract: Distal symmetric polyneuropathy (DSP) related to human immunodeficiency virus 
(HIV) is one of the most common neurologic complications of HIV , possibly affecting as many 
as 50% of all individuals infected with HIV . Two potentially neurotoxic mechanisms have been 
proposed to play a crucial role in the pathogenesis of HIV DSP: neurotoxicity resulting from the 
virus and its products; as well as adverse neurotoxic effects of medications used in the treatment of 
HIV . Clinically, HIV DSP is characterized by a combination of signs and symptoms that include 
decreased deep tendon reflexes at the ankles and decreased sensation in the distal extremities as 
well as paresthesias, dysesthesias, and pain in a symmetric stocking–glove distribution. These 
symptoms are generally static or slowly progressive over time, and depending on the severity, 
may interfere significantly with the patient’s daily activities. In addition to the clinical picture, 
nerve conduction studies and skin biopsies are often pursued to support the diagnosis of HIV DSP. 
Anticonvulsants, antidepressants, topical agents, and nonspecific analgesics may help relieve 
neuropathic pain. Specifically, gabapentin, lamotrigine, pregabalin, amitriptyline, duloxetine, 
and high-dose topical capsaicin patches have been used in research and clinical practice. Further 
research is needed to elucidate the pathogenesis of HIV DSP, thus facilitating the development 
of novel treatment strategies. This review discusses the epidemiology, pathophysiology, clinical 
findings, diagnosis, and management of DSP in the setting of HIV .
Keywords: neuropathy, human immunodeficiency virus, acquired immunodeficiency syndrome, 
AIDS, distal symmetric polyneuropathy, DSP, pain
Introduction
Human immunodeficiency virus (HIV) is a retrovirus that causes progressive failure 
of the immune system in humans. More than 34 million people are infected with HIV 
worldwide, and every year approximately 2.7 million new infections with the virus occur.1 
Since the early descriptions of HIV , distal symmetric polyneuropathy (DSP) has been 
recognized as one of the common neurologic manifestations associated with advanced 
stages of HIV .2 With the introduction of combination antiretroviral therapy (cART) in 
1996, the length of survival of individuals has dramatically improved. For many patients 
in resource-rich countries, HIV is no longer a rapidly progressive, fatal illness but rather a 
chronic condition. However, to this date, DSP remains one of the most common neurologic 
complications of HIV , and it is associated with significant morbidity.3–7
Epidemiology: prevalence and incidence  
of HIV neuropathy
Most estimates of the prevalence of HIV DSP in the cART-era range from 50%–60%, 
although prevalence as low as 21% has been reported.2,6,7 This variability can be in part HIV/AIDS – Research and Palliative Care 2013:5 submit your manuscript | www.dovepress.com
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attributed to the different definitions of HIV DSP, with some 
studies defining DSP as one clinical sign (ie, reduced ankle 
reflexes or reduced pinprick sensation or reduced vibration 
sensation in the feet), some requiring two clinical signs, and 
some using validated screening or diagnostic instruments.7,43,49 
DSP seems to be rare in children with HIV infection,8,9 but 
in an adult, pre-cART population, almost all patients had 
evidence of DSP on autopsy, even those without clinical 
signs and symptoms during their lifetime.10 The incidence 
of HIV DSP varies from 12–25 per 100 person-years.11,12 In 
patient populations on neurotoxic medication, particularly 
stavudine, the incidence tends to be at the higher end of that 
range.13 High doses of stavudine have been associated with 
a higher incidence of DSP than low doses.14
Pathophysiology
DSP has been recognized as a common complication of 
HIV since the late 1980s. Nonetheless, studies investigating 
the macroscopic and microscopic features of HIV DSP in 
humans are scarce, and many of them are limited by small 
sample sizes as well as lack of control groups and clinical 
correlates. In humans, the pathologic hallmarks of HIV neu-
ropathy include distal axonal degeneration, neuronal loss in 
dorsal root ganglia (DRG) of affected nerves, inflammatory 
cell infiltration, and reduced epidermal nerve fiber (EDNF) 
density.10,15
The pathogenesis of HIV DSP in humans is not completely 
understood, but there are several promising hypotheses. Two 
distinct pathophysiologic processes are thought to contribute 
to the development of HIV DSP: direct neurotoxicity of the 
virus and its products and neurotoxicity of cART medications. 
Both processes will be discussed below. For a more detailed 
review of pathogenesis, see Kamerman et al.16
Neurotoxic effects of HIV
Two mechanisms of HIV neurotoxicity have been proposed: 
direct neurotoxicity through infection of neurons with the HIV , 
and indirect neurotoxicity through viral gene products and/
or activation of an inflammatory response to HIV . While it 
remains controversial whether HIV can enter neurons and thus 
be directly neurotoxic,17 there is growing evidence supporting 
the indirect neurotoxicity of HIV through inflammation and 
viral proteins. Several proteins such as trans-activator of tran-
scription, negative regulatory factor (Nef), stromal cell-derived 
factor 1-alpha, and regulated upon activation, normal T cell 
expressed and secreted (RANTES) have been implicated in the 
development of HIV-related central nervous system disease, 
including HIV-associated neurocognitive impairment.
The strongest evidence for indirect neurotoxic effects of 
HIV on the peripheral nervous system stems from research 
investigating the role of glycoprotein (gp)120. Gp120 is 
a well-studied glycoprotein exposed on the surface of the 
HIV envelope, and its involvement in the pathogenesis of 
HIV DSP has been shown using in vitro and in vivo models. 
In vitro, gp120 can induce neuronal cell lysis in cultured DRG 
cells.18 Furthermore, gp120 activates macrophages, which in 
turn release neurotoxic inflammatory mediators such as tumor 
necrosis factor-alpha and interleukin-1.19 Similarly, gp120 has 
been shown to induce Schwann cells to release RANTES, 
which causes dorsal root ganglion neurons to produce tumor 
necrosis factor-alpha, leading to neuronal cell death through 
tumor necrosis factor receptor 1-mediated neurotoxicity.20 In 
vivo, the application of gp120 to the sciatic nerve in rats leads 
to neuronal swelling21 and macrophage infiltration,22 similar 
to inflammatory processes observed in patients with HIV .23 
In a behavior model of pain, rats exposed to gp120 develop 
hypernociception, which can persist for weeks after a single 
application of gp120.21,22,24
Additionally, there is evidence that mitochondrial DNA 
damage is more pronounced in patients with HIV DSP 
compared to HIV patients without DSP and to HIV-negative 
controls. In patients with HIV DSP, the degree of mitochon-
drial DNA damage is higher in the distal sural nerve than in 
the proximally located DRG.25 This spatial distribution sug-
gests that mitochondrial dysfunction may contribute to the 
clinical phenotype of length-dependent neuropathy.
Neurotoxic effects of cART
Nucleoside analog reverse-transcriptase inhibitors (NRTIs) 
such as didanosine, zalcitabine, and stavudine have been 
shown to be associated with DSP.26–29 While the use of 
these NRTIs has significantly declined over the past decade, 
they continue to be part of the mainstay of HIV therapy in 
resource-poor countries, particularly stavudine. Symptomatic 
DSP due to NRTIs is cited as a reason for a change in HIV 
treatment regimens, as symptoms may improve after discon-
tinuation of the offending drug.30,31
DSPs originating from HIV or NRTIs are clinically 
indistinguishable from one another. Nonetheless, different 
pathophysiologic mechanisms have been implicated in the 
development of the clinical phenotype. One hypothesis is that 
NRTIs lead to mitochondrial dysfunction through inhibition 
of mitochondrial DNA polymerase gamma,32,33 which was 
first demonstrated in vitro using PC-12 cells.34 HIV-positive 
patients on zalcitabine were found to have enlarged vacu-
olated mitochondria depleted of DNA.35 In DRG cultures, HIV/AIDS – Research and Palliative Care 2013:5 submit your manuscript | www.dovepress.com
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didanosine has been shown to cause cell death.36 In vivo, 
exposure to zalictabine leads to reduced nerve conduction 
velocities and amplitudes as well as axonal cell loss in 
rabbits.37 In rats, NRTI exposure causes hypersensitivity of 
hind paws, dying-back of EDNFs, and macrophage infiltra-
tion into the DRG.38,39
Synergistic neurotoxic effects  
of HIV and NRTIs
There is evidence from animal studies that the combination of 
HIV and NRTIs may lead to an increased risk of pathological 
findings. For instance, transgenic mice expressing gp120, as 
well as wild-type mice exposed to didanosine, remain free of 
any pathology, but gp120-transgenic mice with didanosine 
exposure exhibit thermal hypersensitivity, loss of unmy-
elinated axons, and reduced EDNF densities.40 In humans, 
the incidence of HIV DSP is higher in patients treated with 
stavudine compared to those on other HIV medications.13
Risk factors
Before the introduction of cART, HIV neuropathy was 
closely associated with advanced immunosuppression, which 
is reflected in a lower CD4 count and a higher viral load.41 
To this day, HIV neuropathy continues to be a predictor of 
death in patients of limited means living in resource-poor 
countries.42
In patients treated with cART, age is the most important 
risk factor for DSP.3,7,26,27,43–48 Stavudine exposure is another 
risk factor that is frequently identified,7,46,48 whereas the 
relationship to other neurotoxic medications exposure is less 
clear.49 Several studies found an association with height26,44–47 
and ethnicity,26,43 but these findings were not replicated by 
other investigators.49 CD4 count in the cART-era does not 
seem to be related to neuropathy,43,50,51 but there are several 
studies suggesting that a lower CD4 nadir represents a risk 
factor for HIV neuropathy.3,27,44 Likewise, viral load is not 
related to HIV neuropathy.26,43,44,50–52 The results regarding 
coinfection with hepatitis C are conflicting, with most studies 
not finding a relationship between hepatitis C coinfection and 
DSP.44,53 One study showed higher rates of neuropathy in HIV 
patients who were coinfected with human T-lymphotropic 
virus type 2.54
Diabetes mellitus (DM) and alcohol abuse are known 
causes of peripheral neuropathy in the general population. In 
patients with HIV , DM increases the risk of DSP,43,44 but the 
results of studies regarding alcohol are inconsistent.6,43,44,50 
Statin use has been shown to correlate with HIV DSP.44 
Furthermore, substance abuse and the number of substances 
used were associated with a higher incidence of HIV DSP 
in a recent study.49 These results suggest that risk factors of 
peripheral neuropathy in the general population exacerbate 
the risk of DSP in HIV patients.
Clinical presentation
Neuropathy in HIV is a predominantly distal, symmetric, 
sensory neuropathy characterized by a variety of clinical 
signs and symptoms. The most commonly encountered clini-
cal signs of HIV DSP are decreased or absent ankle jerks 
and decreased pinprick and vibration sensation involving 
the distal lower extremities.2,6,7,55–57 Weakness and atrophy of 
the extremities are rare.58 HIV DSP can be asymptomatic, 
but many patients experience numbness, tingling, or pain in 
a stocking-glove distribution.7,55,59 In general, the symptoms 
of HIV DSP are first observed in the distal lower extremities 
and may gradually affect more proximal areas. In advanced 
cases, upper extremities can be involved as well. Cramping, 
stabbing, aching, and burning sensations in the affected 
extremities have also been described.55,57 The clinical mani-
festations of HIV DSP tend to be relatively stable over time. 
Distal epidermal denervation has been shown to be associated 
with progression of DSP.51
Diagnosis and differential diagnosis
Diagnosis of HIV DSP remains clinically based on a combi-
nation of typical signs and symptoms in addition to a history 
of HIV infection and possibly NRTI exposure.
There is currently no gold standard for the diagnosis of 
HIV DSP, but several clinical tools have been developed to 
assess this condition in clinical practice and research. The 
most commonly used are the Total Neuropathy Score58 and 
the Brief Peripheral Neuropathy Screen.60
The total neuropathy score combines grading of sen-
sory, motor, and autonomic symptoms, pin and vibration 
sensation, muscle strength, deep tendon reflexes, sural and 
peroneal amplitudes assessed by nerve conduction stud-
ies (NCS), and quantitative sensory testing of vibration 
sensation into a composite score, which correlates with 
the severity of neuropathy. Although originally validated in 
patients with diabetic neuropathy,58 it has been widely used 
in HIV neuropathy.
The Brief Peripheral Neuropathy Screen provides a quick 
and easy assessment of neuropathy at the bedside and does 
not require neurophysiologic testing. Its sensitivity and speci-
ficity compared to the total neuropathy score are 35%–49% 
and 88%–90%, respectively, with a positive predictive value 
of 72%.51,55HIV/AIDS – Research and Palliative Care 2013:5 submit your manuscript | www.dovepress.com
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Use of NCS is not routinely necessary for the diagnosis 
of HIV DSP but may be useful to rule out other conditions. 
If obtained, NCS may reveal slowed conduction velocities 
and reduced sensory nerve action potentials.57,61,62
Skin biopsy of affected areas may show decreased EDNF 
densities and swelling of the nerve terminals.63,64 The degree of 
pathologic changes correlates with clinical pain scores15,65 and 
may predict worsening of symptoms in the next 1–2 years.66 
EDNF has been shown to correlate with age, height, body 
mass index, and duration of neurotoxic therapy,67,68 and in 
some studies but not others, with CD4 count.15,65,67
In addition, quantitative sensory testing is mainly used in 
research settings to measure detection threshold for changes 
in heat, cool, vibration, and to determine pain threshold, 
which may be abnormal in patients with HIV neuropathy,59,69 
and correlate with the degree of EDNF abnormalities found 
on skin biopsy.63,65 Abnormal results are not only found in 
peripheral nerve disorders but also in diseases affecting the 
central nervous system, which is why quantitative sensory 
testing is usually performed in conjunction with other studies 
to help differentiate between the two.70
Nerve biopsies are not routinely indicated for HIV 
DSP but may be considered in atypical cases, for example, 
those with rapid progression or with prominent motor 
involvement.
The differential diagnosis of HIV DSP includes other 
causes of peripheral neuropathy such as DM, vitamin B12 
deficiency, renal or liver impairment, thyroid dysfunction, 
and monoclonal gammopathy. Laboratory tests to assess for 
these conditions are recommended so that adequate treatment 
can be initiated (Table 1).
Treatment
There is currently no US Food and Drug Administration-
approved treatment for HIV neuropathy. Several medications 
have been used off-label for symptomatic control of neuro-
pathic pain, including anticonvulsants, topical treatments, 
antidepressants, and analgesics.
The rationale for the use of these medications is their 
proven benefit in treating neuropathic pain due to diabetic 
neuropathy and postherpatic neuralgia as outlined in the 
recommendations for the management of neuropathic pain 
by the International Association for the Study of Pain71 and 
guidelines for the treatment of diabetic neuropathy by the 
American Academy of Neurology.72 Of note, most of these 
agents have not been shown to be superior to placebo in clini-
cal trials studying HIV DSP, which some authors attribute to 
a pronounced placebo effect in patients with HIV DSP.71
Commonly used medications include the anticonvulsants 
gabapentin, pregabalin, and lamotrigine; topical high-dose 
capsaicin patches; the antidepressants duloxetine and ami-
triptyline; and nonspecific analgesics such as nonsteroidal 
anti-inflammatory drugs, acetaminophen, and opioids 
(Table 2). In general, neuropathic pain remains difficult to 
treat, with only half of the treated population typically report-
ing a significant reduction in pain.73,74 Complete resolution 
of symptoms is rarely achieved; therefore, a reduction in 
symptom severity by 30%–50% may be a more realistic goal 
of therapeutic interventions.75
The following section provides an overview of clinical 
drug trials in HIV neuropathy.
A double-blind, randomized trial has shown that a 
single application of 8% capsaicin patch can alleviate pain 
for several weeks.76 Recently, a study comparing patients 
treated with a single 30-minute or 60-minute application 
of either high-dose (8%) capsaicin or a low-dose (0.04%) 
capsaicin revealed a trend toward greater pain reduction 
in the high-dose capsaicin group. This difference failed to 
reach statistical significance, which was attributed to a larger-
than-expected reduction of pain in the subgroup of patients 
receiving the 60-minute application of low-dose capsaicin.77 
In prior studies, low dose (0.075%) capsaicin and lidocaine 
patches did not lead to improved pain control.78,79
Gabapentin reduced pain significantly and improved sleep 
in a small study with 24 patients.80 Lamotrigine provided 
some pain relief in a study of 227 patients with HIV DSP, 
especially in those patients who were treated with neurotoxic 
medications.81,82 A randomized, double-blind, placebo-
controlled trial of pregabalin failed to demonstrate significant 
improvement of pain, but hyperalgesia was less pronounced 
in participants receiving pregabalin compared to placebo.83 
Amitriptyline is frequently used in diabetic neuropathy; how-
ever, it appears to be less effective in HIV neuropathy based 
on two randomized, placebo-controlled studies.84,85
One small study showed that smoked cannabis improved 
pain more than identical placebo cigarettes; however, this 
benefit disappeared after 7 days.86 A short training program 
in self-hypnosis consisting of three weekly sessions was suc-
cessful at reducing pain scores during a 7-week follow-up in 
a cohort of 36 patients with HIV DSP.87
A randomized, placebo-controlled trial of 250 patients 
investigating the effects of acupuncture did not show sig-
nificant improvement of pain;85 however, a newer study of 
50 patients treated either with acupuncture plus moxibustion 
or a placebo procedure revealed a greater improvement of 
pain in the acupuncture/moxibustion group.88HIV/AIDS – Research and Palliative Care 2013:5 submit your manuscript | www.dovepress.com
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Recently, several trials were conducted based on newer 
pathophysiologic models of HIV DSP. HIV commonly uses 
the C-C chemokine receptor type 5 as a coreceptor to enter its 
target cells. Vicriviroc, a drug that binds to the C-C chemokine 
receptor type 5 and prevents HIV from entering cells, and 
therefore thought to be able to interfere with the pathophysi-
ologic mechanisms causing HIV DSP, did not improve pain 
compared to placebo in a trial of 118 patients with HIV DSP.89 
A trial using prosaptide, a neurotrophic factor, was stopped 
at a planned futility analysis.90 Acetyl-L-carnitine has been 
proposed as a booster of mitochondrial function, but it was 
unsuccessful in alleviating HIV DSP symptoms in a small 
open-label study involving 20 patients and in a random-
ized, placebo-controlled trial of 90 patients.91,92 Although 
neurotrophic growth factor did lead to some improvement of 
DSP symptoms in an open-label study of 200 patients and a 
randomized placebo-controlled trial of 270 patients, it is asso-
ciated with significant adverse effects at the injection sites, and 
it is currently not available clinically.93,94 Trials of memantine, 
mexilitine, and peptide T were unsuccessful.84,95,96
In terms of nonpharmacologic treatment options, a pilot 
study demonstrated improved pain score and sleep index 
scores after using bilateral night splints for three weeks in 
22 patients with HIV neuropathy.97
Lastly, medical management of potentially contributing 
comorbid conditions, such as DM, vitamin deficiencies, and 
alcohol abuse, should be optimized.
Other forms of neuropathy 
associated with HIV
In addition to DSP, HIV can be associated with other disor-
ders of the peripheral nervous system such as mononeuropa-
thies, mononeuritis multiplex, inflammatory demyelinating 
polyneuropathy, progressive polyradiculopathy, and auto-
nomic neuropathy.98–100
HIV-infected individuals, particularly those with DSP, may 
be at increased risk for superimposed mononeuropathies. The 
most common mononeuropathies include median neuropathy 
at the wrist (ie, carpal tunnel syndrome), ulnar neuropathy at 
the elbow, and peroneal neuropathy at the fibular head. Facial 
nerve palsy, often referred to as Bell’s palsy, is commonly an 
idiopathic, presumably inflammatory condition. However, in 
the setting of HIV , particularly with advanced immunosup-
pression, other etiologies should be considered including 
varicella zoster virus, meningeal lymphomatosis, aseptic 
meningitis, syphilis, or tuberculosis. In such patients, a more 
comprehensive work-up may be warranted to distinguish these 
etiologies from idiopathic forms.101–103
Mononeuritis multiplex manifests as painful, progressive, 
sensory and motor deficits in multiple nerve distributions that 
may become confluent. It is a rare complication of HIV , and 
while the symptoms can be self-limited, a rapidly progres-
sive variant caused by cytomegalovirus infection of periph-
eral nerves has been described in the setting of advanced 
immunosuppression.104–106
Two forms of inflammatory demyelinating polyneuropa-
thy (IDP) have been described in HIV patients: an acute form 
of IDP, or Guillain–Barré syndrome, with rapidly progres-
sive symptoms, and a chronic form characterized by slower 
progression or by a relapsing–remitting course.107 Clinically, 
both forms present with ascending muscle weakness and 
areflexia in addition to paresthesias. In HIV-negative patients 
with IDP, cerebrospinal fluid studies typically reveal albu-
minocytologic dissociation; that is, an elevated cerebrospinal 
fluid protein level in the absence of significant pleocytosis. In 
HIV-positive patients, a mild lymphocytic pleocytosis with 
elevated protein levels is commonly found in asymptomatic 
patients with high CD4 counts,108,109 and is therefore less 
specific for IDP in this patient population.
The clinical picture of polyradiculopathy is character-
ized by progressive sensory, motor, and reflex changes in a 
radicular distribution. In HIV patients, progressive polyra-
diculopathy may be secondary to infectious or neoplastic 
etiologies such as lymphoma, cytomegalovirus, treponema 
pallidum, or mycobacterium tuberculosis.110–113
Manifestations of autonomic neuropathy include ortho-
static hypotension, gastroparesis, diarrhea and constipation, 
xerostomia, xerophthalmia, urinary incontinence, sexual 
dysfunction, sweating abnormalities, and sluggish pupillary 
Table 1 Laboratory studies in the initial evaluation of human 
immunodeficiency virus patients presenting with distal symmetric 
polyneuropathy
Basic metabolic panel
Liver function tests
Hemoglobin A1c
Vitamin B12, folate
Thyroid function tests
Serum, urine protein electrophoresis and serum immunofixation
Hepatitis C virus serology
Table 2 Pharmacological treatment of neuropathic pain
Discontinuation of neurotoxic medication
Anticonvulsants: gabapentin, lamotrigine, pregabalin
Topical anesthetics: capsaicin, lidocaine
Antidepressants: duloxetine, amitriptyline
Analgesics: NSAIDs, acetaminophen, opioid analgesics
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.HIV/AIDS – Research and Palliative Care 2013:5 submit your manuscript | www.dovepress.com
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reaction.114 Recent studies suggest that autonomic neuropathy 
is a common comorbidity of HIV DSP, affecting more than 
half of all HIV DSP patients and is associated with predictors 
of mortality as summarized by the Veterans Aging Cohort 
Study Index.100,115,116
NCS and electromyography, cerebrospinal fluid studies, 
neuroimaging and autonomic function tests may be helpful to 
distinguish between HIV DSP and these other less common 
forms of neuropathy.
Conclusion and future directions
HIV DSP is the most common neurologic complication of 
HIV . Several mechanisms may be involved in the pathogen-
esis of HIV DSP such as neurotoxic effects of the virus and 
its gene products as well as neurotoxic medications used for 
the treatment of HIV . Clinically, HIV DSP is characterized 
by sensory symptoms such as dysethesias and paresthesias 
with symmetric involvement of the distal extremities. Signs 
of HIV DSP include decreased deep tendon reflexes and 
decreased sensation in a stocking-glove distribution. While 
the diagnosis of HIV DSP remains largely clinical, other 
conditions that lead to distal sensory neuropathies need to 
be excluded. The treatment of HIV DSP remains difficult. 
Topical medications such as high-dose capsaicin patches, and 
anticonvulsants have yielded the most promising results thus 
far. Additional research is needed to elucidate the mecha-
nisms leading to HIV DSP, which in turn will allow for the 
development of targeted treatment strategies.
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